Oraverse Versus Laser

NCT05473858 · tracked via the Priya Life Science Egypt tracker

Sponsor

sara nabil

Phase

Phase 3

Started

2021-12-10

Last updated

2026-04-06

Condition(s) studied

Reversal of Local Anesthesia in Children

Investigational drug(s) / intervention(s)

OraVerse Injectable Productdiode laserAnaesthesia only

OraVerse Injectable Product: injection of oraverse,

diode laser: patient exposed to diode laser

Anaesthesia only: Patient exposed to anaesthesia without any more intervention

Study summary

clinically assess the reversal of articaine 4% of two different concentration of vasoconcentration soft-tissue local anesthesia in pediatric dentistry using Diode Laser and Oraverse

Eligibility

Sex

ALL

Min age

6 Years

Max age

10 Years

Healthy volunteers

Accepted

Inclusion Criteria: 1. Patients who need to be treated under anesthesia by injecting mandibular first molar infiltration. 2. Cooperative children aged 6 to 10 years old with the ability to understand and respond to the sensation of soft tissue -

Primary outcome measure(s)

reversal of local anasthesia — 30 minute
patient free of lip numbness

Trial sites (1)

Facility	City	Region	Status
Dr.sara nabil	Cairo	Egypt	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05473858 on ClinicalTrials.gov ↗ ← All trials in Egypt